

2025-2026 ECCO Annual Disclosure of Potential Conflict of Interest

Name: Kobayashi, Taku

In its aim to foster transparency and based on the ICJME Disclosure Form for Potential Conflict of Interest, ECCO has collected the according information of ECCO Officers and invited congress faculty at ECCO'26 via its online submission system.

The CoI Disclosure information is updated every autumn in line with the respective Congress business year. The purpose is to have a comprehensive declaration of interests for ECCO activities.

In case different disclosure answers have been submitted for different ECCO'26 presentations, the 2025-2026 ECCO Annual Disclosure of Potential Conflict of Interest on the association website shows the merged version of the answers to the following questions:

- Disclosure statement:
 - I have no potential conflict of interest to disclose
 - I have potential conflict of interest to disclose

- Potential Conflict of Interest can involve: grants, honoraria, shares, paid positions on advisory boards, etc.:
 - Grant
 - Personal Fees
 - Non-financial support
 - Other

Disclosures statement based on answers received:

Grant:AbbVie, Alfresa Pharma, Bristol Myers Squibb, Celtrion, EA Pharma, Gilead Sciences, Kyorin Pharmaceutical, Miyarisan, Mochida Pharmaceutical, Nippon Kayaku, Otsuka Holdings, Pfizer, Sekisui Medical, Takeda, Zeria Pharmaceutical
Personal Fees:AbbVie, Alfresa Pharma, Alimentiv, Bristol Myers Squibb, Celltrion, Covidien, EA Pharma, Eli Lilly, Ferring Pharmaceuticals, Galapagos, Gilead Sciences, Janssen, JIMRO, Kissei Pharmaceutical, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, MSD, Nippon Kayaku, Pfizer, Sekisui Medical, Takeda Pharmaceutical, Zeria Pharmaceutical